Shilpa Medicare Limited
Financial trend (100/100) does the heavy lifting; valuation (38/100) is the drag.
Fair valueShilpa Medicare Limited earns a Buy from StocksWizard, with a blended score of 70/100. At ₹611.25 it trades above our blended DCF and relative-multiples fair value of ₹531.14, about 13% downside to that estimate — we read it as overvalued by 13%. On 48.8x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 5% below its 52-week high of ₹645.75 and 129% above the low of ₹267. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9. The average analyst target of ₹603 implies about 1% downside across 3 analysts. It clears 8 of 13 investability checks, with durability 63, valuation 48 and momentum 97 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹424.91.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-5.34% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy70Piotroski F-score 7/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 9.8%
- Pass: Low debt (D/E < 0.5): 0.25x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 32%
- Pass: Earnings growing: 645%
- Pass: Net margin ≥ 10%: 15.8%
- Fail: Current ratio > 1.5: 1.31
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 7.27
- Pass: Piotroski ≥ 7: 7/9
Quarterly results
Annual financials
Shareholding
- Promoter57.0%
- Institutions10.3%
- Public & other32.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (15.8%).
- Financially solid — Altman Z 7.27.
- High Piotroski quality score (7/9).
Opportunities
- Earnings growing (645% YoY).
- Revenue growing (32% YoY).
About Shilpa Medicare Limited
Shilpa Medicare Limited manufactures and sells active pharmaceutical ingredients, finished dosage formulations, and biosimilars across India, the United States, Europe, and other international markets. The company also operates as a contract development and manufacturing organization, offering both oncology and non-oncology APIs including anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, and bicalutamide.
Shilpa Medicare Limited — frequently asked questions
Is Shilpa Medicare Limited a buy, hold or sell?
StocksWizard currently rates Shilpa Medicare Limited (SHILPAMED) a Buy, based on a blended score of 70/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Shilpa Medicare Limited's fair value?
Our blended DCF and relative-valuation model estimates Shilpa Medicare Limited's fair value at about ₹531.14, versus a current price of ₹611.25 — roughly 13% downside. On that basis the stock looks overvalued by 13%.
Is Shilpa Medicare Limited financially healthy?
Shilpa Medicare Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9.
How has Shilpa Medicare Limited's share price performed?
Shilpa Medicare Limited is up 44% over three months, and last traded at ₹611.25. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.